Literature DB >> 12794259

SLE and infections.

Gisele Zandman-Goddard1, Yehuda Shoenfeld.   

Abstract

Infections are common in systemic lupus erythematosus (SLE), and remain a source of mortality. The types of infections (such as pneumonia, urinary tract infection, cellulitis, and sepsis) in SLE patients are similar to the general population and include the same pathogens (Gram-positive and Gram-negative). SLE patients may also develop opportunistic infections, especially when treated with immunosuppressive agents. As a high-risk population, identification and treatment of chronic infections such as tuberculosis, hepatitis B, or human immunodeficiency virus (HIV), are important prior to the institution of immunosuppression to prevent reactivation or exacerbation of the infection. A common caveat is to distinguish between a lupus flare and an acute infection; judicious use of corticosteroids and cytotoxic drugs is critical in limiting infectious complications. The risk factors associated with susceptibility to disease include severe flares, active renal disease, treatment with moderate or high doses of corticosteroids and/or immunosuppressive agents, and others. Genetic factors (complement deficiencies, mannose-binding lectin, Fcgamma III, granulocyte macrophage colony-stimulating factor [GM-CSF], osteopontin) may predispose certain SLE patients to develop infections. Parameters including C-reactive protein (CRP) and adhesion molecules may help to differentiate an infectious disease from an exacerbation of the disease. Finally, the mechanism of molecular mimicry by specific microbial agents may play a role in the induction of SLE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794259     DOI: 10.1385/CRIAI:25:1:29

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  52 in total

1.  Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo.

Authors:  Azzudin E Gharavi; Silvia S Pierangeli; Ricardo G Espinola; Xiaowei Liu; Margaret Colden-Stanfield; E Nigel Harris
Journal:  Arthritis Rheum       Date:  2002-02

Review 2.  Infection in systemic lupus erythematosus.

Authors:  M Petri
Journal:  Rheum Dis Clin North Am       Date:  1998-05       Impact factor: 2.670

3.  Systemic lupus erythematosus: mortality and survival in Argentina. A multicenter study.

Authors:  V Bellomio; A Spindler; E Lucero; A Berman; M Santana; C Moreno; R P Hidalgo; S Paira; C Graf; J A Maldonado Cocco; G Citera; M S Arriola; G Gómez; J C Barreira; O Messina; C Asnal; D Carrillo; A Gervilla; L García; M Máscolo; D De la Sota M; G Rosso; L F Somma; R F Sosa; O Rillo; J A Caracciolo; G Lancioni; A Gómez
Journal:  Lupus       Date:  2000       Impact factor: 2.911

4.  Human parvovirus B19 infection in children: uncommon clinical presentations.

Authors:  Judith Barash; Doron Dushnitzky; Dalia Sthoeger; Rita Bardenstein; Yigal Barak
Journal:  Isr Med Assoc J       Date:  2002-10       Impact factor: 0.892

5.  Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients.

Authors:  P Garred; A Voss; H O Madsen; P Junker
Journal:  Genes Immun       Date:  2001-12       Impact factor: 2.676

Review 6.  The role of Epstein-Barr virus in systemic lupus erythematosus.

Authors:  M T McClain; J B Harley; J A James
Journal:  Front Biosci       Date:  2001-10-01

Review 7.  Human parvovirus B19 infection: its relationship with systemic lupus erythematosus.

Authors:  S Trapani; M Ermini; F Falcini
Journal:  Semin Arthritis Rheum       Date:  1999-04       Impact factor: 5.532

8.  When typical is atypical: mycobacterial infection mimicking cutaneous vasculitis.

Authors:  M-M Gordon; H E Wilson; F R Duthie; B Jones; M Field
Journal:  Rheumatology (Oxford)       Date:  2002-06       Impact factor: 7.580

Review 9.  False-positive human immunodeficiency virus testing in patients with lupus erythematosus.

Authors:  H R Barthel; D J Wallace
Journal:  Semin Arthritis Rheum       Date:  1993-08       Impact factor: 5.532

10.  The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea.

Authors:  J E Yun; S W Lee; T H Kim; J B Jun; S Jung; S C Bae; T Y Kim; D H Yoo
Journal:  Clin Exp Rheumatol       Date:  2002 Mar-Apr       Impact factor: 4.473

View more
  24 in total

1.  Machine learning analysis of the relationship between changes in immunological parameters and changes in resistance to Listeria monocytogenes: a new approach for risk assessment and systems immunology.

Authors:  Zhifa Liu; Changhe Yuan; Stephen B Pruett
Journal:  Toxicol Sci       Date:  2012-06-13       Impact factor: 4.849

2.  Fatal tuberculous meningitis caused by immune restoration disease.

Authors:  Hagen B Huttner; Rainer Kollmar; Andreas Hug; Fabian Meisel; Bodo Kress; Stefan Schwab
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

Review 3.  CD24: from a Hematopoietic Differentiation Antigen to a Genetic Risk Factor for Multiple Autoimmune Diseases.

Authors:  Yixin Tan; Ming Zhao; Bo Xiang; Christopher Chang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

4.  Long-Term 'Self-Managed' Immunosuppressive Treatment Resulting in Death due to Fulminant Hepatitis B : Medical Malpractice or Patient's Autolesionism?

Authors:  Roberto Manfredi; Sergio Sabbatani; Francesco Chiodo
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 5.  Orthopedic surgery and its complication in systemic lupus erythematosus.

Authors:  Anselm Mak
Journal:  World J Orthop       Date:  2014-01-18

Review 6.  Bacterial Amyloids: The Link between Bacterial Infections and Autoimmunity.

Authors:  Lauren Nicastro; Çagla Tükel
Journal:  Trends Microbiol       Date:  2019-08-15       Impact factor: 17.079

7.  Bacterial lipopolysaccharide both renders resistant mice susceptible to mercury-induced autoimmunity and exacerbates such autoimmunity in susceptible mice.

Authors:  M Abedi-Valugerdi; C Nilsson; A Zargari; F Gharibdoost; J W DePierre; M Hassan
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

8.  Tuberculosis in SLE patients: rare diagnosis, risky treatment.

Authors:  Kanokpan Ruangnapa; Pornsak Dissaneewate; Prayong Vachvanichsanong
Journal:  Clin Exp Med       Date:  2014-08-07       Impact factor: 3.984

9.  Significantly higher percentage of circulating CD27(high) plasma cells in systemic lupus erythematosus patients with infection than with disease flare-up.

Authors:  Deng-Ho Yang; Deh-Ming Chang; Jenn-Haung Lai; Fu-Huang Lin; Chen-Hung Chen
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

10.  Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report.

Authors:  Iain J Abbott; Christina C Chang; Matthew J Skinner; Alison Street; Greg Perry; Catriona McLean; Edwina J Wright; Paul U Cameron
Journal:  J Med Case Rep       Date:  2009-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.